Although the exact implication of disulfidptosis activity on cancer patients’ immune characteristics is still unknown, two disulfidptosis-related gene SLC7A11 and SLC3A2, has been reported to play a role in the immune process during tumorigenesis. This evidence concerns the gene SLC3A2 and cancer.